Clinical trials: Melphalan, active
Acute Myeloid Leukemia, Graft Versus Host Disease
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
This phase I trial tests the safety, side effects and effectiveness of emapalumab with post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil in preventing graft-versus-host disease (GVHD) in patients with acute…
- Conditions
- Acute Myeloid Leukemia, Graft Versus Host Disease, Myelodysplastic Syndrome
- Trial name
- NCT06996119
- Testing
- Biospecimen Collection, Busulfan, Computed Tomography
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Hematological Malignancy
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
Now haplo stem cell transplant using bone marrow or peripheral blood is becoming more feasible with better regimens to prevent graft versus host disease (GVHD) like post transplant cyclophosphamide , tacrolimus, mycophenolate .
- Trial name
- NCT03850366
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Henry Ford Health System
Multiple Myeloma
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
With this study - Total Therapy IIIB - researchers are extending the findings of Total Therapy III based what they have learned from the first two studies (Total Therapy I and II), with new research strategies designed to explore…
- Trial name
- NCT00572169
- Testing
- Velcade, Thalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- University of Arkansas
Primary Myelofibrosis, Secondary Myelofibrosis
Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis
This phase II trial studies how well administering ruxolitinib before, during, and after allogeneic hematopoietic stem cell transplantation works in preventing graft versus host disease and improving transplant outcomes in…
- Trial name
- NCT04384692
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Bone Marrow Failure Syndrome, Severe Aplastic Anemia
CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation
This study's goal is to determine the frequency and severity of acute graft versus host disease, to evaluate incidence of primary and secondary graft rejection, to assess event free survival and overall survival, to determine the…
- Conditions
- Bone Marrow Failure Syndrome, Severe Aplastic Anemia, Severe Congenital Neutropenia, Amegakaryocytic Thrombocytopenia
- Trial name
- NCT01966367
- Testing
- CD34 Stem Cell Selection Therapy
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Diane George
Myeloma
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy
There have been four previous Total Therapy (TT1 through IIIB) studies for multiple myeloma at the MIRT from 1989 to present. Results have shown that participants treated on these studies had better outcomes (meaning they have…
- Trial name
- NCT00871013
- Testing
- Melphalan, Velcade, Thalidomide
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- University of Arkansas
Diffuse Large B Cell Lymphoma
Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
This is an open-label, multicentre, randomised phase II trial in relapsed or refractory diffuse large B-cell lymphoma.
- Trial name
- P+R-ICE (NCT05221645)
- Testing
- Pembrolizumab, Rituximab, Ifosfamide
- Where
- 2 sites in United Kingdom
- Volunteers
- 65 people
- Sponsor
- University of Southampton
Non-Hodgkin's Lymphoma
High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
The purpose of this study is to test the safety of delivering the patients' own immune cells, called T cells, after the high-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT).
- Trial name
- NCT01840566
- Testing
- Carmustine, Etoposide, Cytarabine
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer Metastatic
Improving Public Cancer Care by Implementing Precision Medicine in Norway
IMPRESS-Norway is a prospective, non-randomized clinical trial evaluating efficacy of commercially available, anti-cancer drugs prescribed for patients with advanced cancer diagnosed with potentially actionable alterations as…
- Trial name
- IMPRESS-N (NCT04817956)
- Testing
- Atezolizumab
- Where
- 17 sites in Norway
- Volunteers
- 3,000 people
- Sponsor
- Oslo University Hospital
Newly Diagnosed Multiple Myeloma
Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients
Multiple myeloma (MM) is a malignant disease of the BM characterized by clonal expansion of plasma cells. Current guidelines recommend that newly diagnosed transplant-eligible patients with multiple myeloma (NDMMTE) shall undergo…
- Trial name
- ELIAS (NCT05665140)
- Testing
- Isatuximab, Lenalidomide, Bortezomib
- Where
- 6 sites in Germany
- Volunteers
- 100 people
- Sponsor
- University Hopsital Schleswig Holstein Campus Lübeck
Acute Leukemia, Acute Lymphoblastic Leukemia
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marrow from a deceased donor in patients with acute and chronic leukemias, myelodysplastic syndrome, and certain…
- Conditions
- Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia
- Trial name
- NCT05589896
- Testing
- Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC)
- Where
- 9 sites in United States
- Volunteers
- 12 people
- Sponsor
- Ossium Health, Inc.
Smoldering Multiple Myeloma
Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma
Patients included in the study will receive induction treatment during 6 months, followed by receive high-dose therapy followed by peripheral blood stem cell transplantation.
- Trial name
- NCT02415413
- Testing
- carfilzomib, Lenalidomide, Dexamethasone
- Where
- 16 sites in Spain
- Volunteers
- 90 people
- Sponsor
- PETHEMA Foundation
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
This phase I trial is to find out the best dose, possible benefits and/or side effects of 90Y-DOTA-anti-CD25 basiliximab given together with fludarabine, melphalan, and total marrow and lymphoid irradiation (TMLI) in treating…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
- Trial name
- NCT05139004
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Basiliximab, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- City of Hope Medical Center
Melanoma, In-Transit Metastasis
Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion
To evaluate safety and the effect of isolated limb perfusion together with nivolumab as a way to increase efficacy and give further insights in early immunological mechanisms.
- Trial name
- NivoILP (NCT03685890)
- Testing
- Nivolumab, Isolated limb perfusion (ILP)
- Where
- 4 sites in Netherlands, Sweden
- Volunteers
- 74 people
- Sponsor
- Vastra Gotaland Region
Hematologic Malignancy, Bone Marrow Transplant
Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation
The purpose of this study is to evaluate the safety of reducing and ultimately eliminating anti-thymocyte globulin (ATG) from the haplo-cord transplant conditioning regimen and replacing it with tocilizumab, an IL-6 receptor…
- Trial name
- NCT04395222
- Testing
- Tocilizumab, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Weill Medical College of Cornell University
Multiple Myeloma, Amyloidosis
Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.
Captisol Enabled Melphalan, is a new formulation of the standard of care melphalan chemotherapy that in packaged in an inactive substance that is believed to help the chemotherapy be more stable (meaning that it doesn't lose its…
- Trial name
- NCT02909036
- Testing
- Melphalan, Pegfilgrastim, Autologous Hematopoietic Progenitor Cell Transplant
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
This study will assess whether adding one of the newest multiple myeloma therapies, daratumumab, into the Total Therapy approach helps patients live longer with fewer side effects
- Trial name
- NCT03004287
- Testing
- Carfilzomib, Thalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Arkansas
Multiple Myeloma
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
In this research study, we are looking to explore the drug combination, lenalidomide, bortezomib and dexamethasone alone or when combined with autologous stem cell transplantation to see what side effects it may have and how well…
- Trial name
- DFCI 10-106 (NCT01208662)
- Testing
- Lenalidomide, Bortezomib, Dexamethasone
- Where
- 46 sites in United States
- Volunteers
- 729 people
- Sponsor
- Paul Richardson, MD
Multiple Myeloma, Minimal Residual Disease
Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not
The goal of this observational study is to compare the efficacy and safety of autologous hematopoietic stem-cell transplantation (ASCT) versus non ASCT regimens in primary multiple myeloma patients achieved MRD negativity after…
- Trial name
- NCT06463717
- Testing
- Transplant, Autologous, Chemotherapy drug
- Where
- China
- Volunteers
- 210 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Hemophilia A
Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A
This is a Phase I study. This research study is being conducted to find new ways to treat severe hemophilia A. This study is a gene therapy study.
- Trial name
- NCT03818763
- Testing
- Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Medical College of Wisconsin